NHIC, Novartis unable to agree on Glivec price

Published: 2009-04-09 06:59:00

Updated: 2009-04-09 06:59:00

The National Health Insurance Corporation (NHIC) and Novartis Korea adjourned on April 6 two occasion of price negotiation over Glivec with no agreement on how to cope with “reasonable” price.

Now all eyes are on the Ministry for Health, Welfare and Family Affair committee's decision on the price of Glivec, a drug used to treat treating chronic myelogenous leukemia, gastrointenstinal stromal...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.